Cohera Medical’s Engineers Honored for Design Excellence among Worldwide Medical and Scientific Engineers
PITTSBURGH, Pa., April 2, 2012– Cohera Medical, a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that its lead product, TissuGlu® Surgical Adhesive, is a finalist for the 2012 Medical Design Excellence Awards in the General Hospital Devices and Therapeutic Products category.
The Medical Design Excellence Awards is the medical device industry’s premier design awards competition and is the only awards program that exclusively recognizes contributions and advances in the design of medical products. The program recognizes the achievements of medical product manufacturers and the many people behind the scenes – engineers, scientists, designers, and clinicians – who are responsible for the groundbreaking innovations that are changing the face of healthcare. Entries are evaluated on the basis of their design and engineering features.
TissuGlu is an internal surgical adhesive for large flap surgeries, such as abdominoplasties, that helps reduce fluid accumulation and the need for postsurgical drains. Its unique chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may provide the patient with a quicker return to normal activity.
“We are very pleased that TissuGlu Surgical Adhesive has been recognized as one of this year’s most innovative medical products in the industry by the MDEA judges,” said Patrick Daly, President & CEO, Cohera Medical. “This award is a reflection of Cohera’s excellence in designing cutting-edge technology that will help surgeons improve the overall care of their patients.”
Currently, most patients who undergo abdominoplasty procedures and other flap procedures require the insertion of drains to remove fluids that accumulate under the skin at the surgical site. In some cases, drainage is inadequate and the excess fluid accumulation (seroma) requires additional procedures for removal. TissuGlu adheres the tissue flap created during the procedure to the underlying tissue, helping to reduce the fluid that can accumulate in the space and ultimately reducing the time to drain removal. The use of TissuGlu may shorten the length of time that drains need to be in place, leading to a more comfortable recovery and a quicker return to normal activity for patients.
This year’s MDEA finalists will be announced in the April Issue of Medical Device and Diagnostic Industry (www.mddionline.com) magazine. The winners will be announced in May at a special presentation ceremony held in conjunction with the Medical Design & Manufacturing (MD&M) East Event (www.MDMEast.com), May 22-24, 2012, at the Pennsylvania Convention Center in Philadelphia.
About Cohera Medical
Cohera Medical, Inc.® is a leading innovator and developer of absorbable surgical adhesives and sealants. The Company’s first product, TissuGlu® Surgical Adhesive, is an internal surgical adhesive for large flap surgeries, such as abdominoplasty (tummy tuck), that eliminates or reduces fluid accumulation and the need for post surgical drains. TissuGlu’s chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may enable faster recovery. TissuGlu has received CE Marking approval to be sold in the European Union (EU). Cohera Medical is also developing a unique and proprietary bowel sealant, and a strong adhesive for mesh fixation. Outside of the EU, TissuGlu and the other Cohera products are currently indicated for investigational use only and have not yet been approved for sale or marketing by the Food and Drug Administration (FDA) in the U.S. or in any other market. For more information, visit www.coheramed.com.
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company’s future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.
Zer0 to 5ive